[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571856":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":45,"collaborators":49,"id":51,"slug":10,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Group Assignment",null,"Each subject receive a single intravenous injection of 68Ga\u002F18F-Exendin 4, and undergo PET\u002FCT imaging within the specificed time.",[13],"Diagnostic Test: 18F\u002F68Ga-Exendin 4",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","18F\u002F68Ga-Exendin 4",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Qiusong Chen, MD","CONTACT","+862260362190","qs_c8@hotmail.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Haonan Yu, MD","+8613821000597","dreamadam@126.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Tianjin Medical University General Hospital","RECRUITING","Tianjin","Tianjin Municipality","300052","China",{"type":38,"coordinates":39},"Point",[40,41],117.17667,39.14222,{"lat":41,"lon":40},[44],{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Shaobo Yao, PhD","Prof.",[50],{"name":31,"class":6},"100571856",false,"NCT06725693","Glucagon-like Peptide-1 Receptor PET\u002FCT in GLP-1R Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","80 Years",{"count":61,"type":62},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga\u002F18F-Exendin 4 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.",[67,68,69,70],"GLP1-R-related Disease","Tumor","Insulinoma","Positron Emission Tomography",[72,73],"PET\u002FCT","GLP1-R","2025-02-07",{"date":76,"type":77},"2025-02-11","ACTUAL",{"date":79,"type":77},"2019-02-01",{"date":81,"type":62},"2027-11-01",{"name":5,"class":6},1]